Literature DB >> 26638919

Management of recurrence after initial surgery for malignant pleural mesothelioma: a mini-review.

Semih Halezeroğlu1, Marcello Migliore2.   

Abstract

Recurrence after surgery in the multimodality therapy for malignant pleural mesothelioma is a common problem. As the majority of patients experience not only local but also distant metastases, a systemic treatment strategy in addition to local control measures remains necessary. Nevertheless, none of the chemotherapy regimens have achieved clinical success. Local management modalities such as stereotaxic treatments, cryoablation and redo surgery on the other hand have promising results, but provide palliative outcomes.

Entities:  

Keywords:  failure; mesothelioma; recurrence; surgery

Mesh:

Year:  2015        PMID: 26638919     DOI: 10.2217/fon.15.312

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  4 in total

1.  A case of surgically treated bilateral metachronous malignant pleural mesothelioma.

Authors:  Mehmet Ali Bedirhan; Levent Cansever; Adnan Yöney; Celalettin Kocatürk
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-01-01       Impact factor: 0.332

2.  Salvage debulking surgery and hyperthermic intrathoracic chemotherapy for massive recurrent mesothelioma in the mediastinum.

Authors:  Shi Sum Poon; Caterina Alberti; Marco Nardini; Marcello Migliore
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

3.  Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation.

Authors:  Nishant S Kulkarni; Bhuvaneshwar Vaidya; Vineela Parvathaneni; Debarati Bhanja; Vivek Gupta
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

4.  Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma.

Authors:  Sabrina Banella; Eride Quarta; Paolo Colombo; Fabio Sonvico; Antonella Pagnoni; Fabrizio Bortolotti; Gaia Colombo
Journal:  Pharmaceutics       Date:  2021-03-09       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.